Table 1 Clinicopathologic characteristics of ILC in this study
From: EZH2 expression in invasive lobular carcinoma of the breast
| Â | Â | EZH2 expression N(%) | P | |||
|---|---|---|---|---|---|---|
| Â | Total N(%) | 0% to 5% | 5% to 25% | 25% to 50% | >50% | Â |
Age at diagnosis | Â | Â | Â | Â | Â | 0.255 |
  <50 | 28 (57.1) | 3 (37.5) | 6 (75.0) | 2 (33.3) | 17 (63.0) |  |
  ≤50 | 21 (42.9) | 5 (62.5) | 2 (25.0) | 4 (66.7) | 10 (37.0) |  |
Menstrual status | Â | Â | Â | Â | Â | 0.472 |
  Premenopausal | 27 (55.1) | 4 (50.0) | 6 (75.0) | 2 (33.3) | 15 (55.6) |  |
  Postmenopausal | 22 (44.9) | 4 (50.0) | 2 (25.0) | 4 (66.7) | 12 (44.4) |  |
Body mass index | Â | Â | Â | Â | Â | 0.647 |
  Underweight (<20) | 3 (6.1) | 1 (12.5) | 0 (0) | 1 (16.7) | 1 (3.7) |  |
  Normal (≥20, <25) | 29 (59.2) | 4 (50.0) | 6 (75.0) | 2 (33.3) | 17 (63.0) |  |
  Overweight (≥25) | 17 (34.7) | 3 (37.5) | 2 (25.0) | 3 (50.0) | 9 (33.3) |  |
Side of primary tumor | Â | Â | Â | Â | Â | 0.587 |
  Left | 25 (51.0) | 5 (62.5) | 4 (50.0) | 4 (66.7) | 12 (44.4) |  |
  Right | 21 (42.9) | 3 (37.5) | 3 (37.5) | 1 (16.7) | 14 (51.9) |  |
  Bilateral | 3 (6.1) | 0 (0) | 1 (12.5) | 1 (16.7) | 1 (3.7) |  |
Multifocality | Â | Â | Â | Â | Â | 0.981 |
  Monofocal | 38 (77.6) | 6 (75.0) | 6 (75.0) | 5 (83.3) | 21 (77.8) |  |
  Multifocal | 11 (22.4) | 2 (25.0) | 2 (25.0) | 1 (16.7) | 6 (22.2) |  |
T stage | Â | Â | Â | Â | Â | 0.770 |
  T1 | 22 (44.9) | 4 (50.0) | 5 (62.5) | 2 (33.3) | 11 (40.7) |  |
  T2 | 23 (46.9) | 3 (37.5) | 3 (37.5) | 4 (66.7) | 13 (48.1) |  |
  T3 | 4 (8.2) | 1 (12.5) | 0 (0) | 0 (0) | 3 (11.1) |  |
Lymph node metastasis | Â | Â | Â | Â | Â | 0.403 |
  N0 | 28 (57.1) | 6 (75.0) | 6 (75.0) | 4 (66.7) | 12 (44.4) |  |
  N1 | 8 (16.3) | 1 (12.5) | 2 (25.0) | 0 (0) | 5 (18.5) |  |
  N2 | 4 (8.2) | 1 (12.5) | 0 (0) | 0 (0) | 3 (11.1) |  |
  N3 | 9 (18.4) | 0 (0) | 0 (0) | 2 (33.3) | 7 (25.9) |  |
Nuclear grade | Â | Â | Â | Â | Â | 0.025 |
  1 | 7 (14.3) | 4 (50.0) | 2 (25.0) | 0 (0) | 1 (3.7) |  |
  2 | 32 (65.3) | 4 (50.0) | 5 (62.5) | 5 (83.3) | 18 (66.7) |  |
  3 | 10 (20.4) | 0 (0) | 1 (12.5) | 1 (16.7) | 8 (29.6) |  |
Estrogen receptor status | Â | Â | Â | Â | Â | 0.629 |
  Negative | 13 (26.5) | 1 (12.5) | 3 (37.5) | 1 (16.7) | 8 (29.6) |  |
  Positive | 36 (73.5) | 7 (87.5) | 5 (62.5) | 5 (83.3) | 19 (70.4) |  |
Progesterone receptor status | Â | Â | Â | Â | Â | 0.615 |
  Negative | 10 (20.4) | 2 (25.0) | 2 (25.0) | 0 (0) | 6 (22.2) |  |
  Positive | 39 (79.6) | 6 (75.0) | 6 (75.0) | 6 (100.0) | 21 (77.8) |  |
Cerb-B2 status | Â | Â | Â | Â | Â | 0.410 |
  Negative | 39 (79.6) | 5 (62.5) | 7 (87.5) | 4 (66.7) | 23 (85.2) |  |
  Positive | 10 (20.4) | 3 (37.5) | 1 (12.5) | 2 (33.3) | 4 (14.8) |  |
p53 | Â | Â | Â | Â | Â | 0.093 |
  Negative | 37 (75.5) | 4 (50.0) | 5 (62.5) | 4 (66.7) | 24 (88.9) |  |
  Positive | 12 (24.5) | 4 (50.0) | 3 (37.5) | 2 (33.3) | 3 (11.1) |  |